Emicizumab (Biosimilar Reference Antibody) (F9/Factor IX)
Emicizumab (Biosimilar Reference Antibody) (F9/Factor IX)-RA0826-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.
Emicizumab (Biosimilar Reference Antibody) (F9/Factor IX)

Catalog: 

RA0826

Target

F9/Factor IX

Isotype

IgG4 - kappa

Applications

ELISA;FC;Functional Assays;IF

Reactivities

Human

Size (＄)：

100 μg-50;1 mg-210;5 mg-500;10 mg-800;25 mg-1750;50 mg-3000;100 mg-4600

Data Sheet

Material Safety Data Sheet

Certificate of Analysis

Product Description

Emicizumab is a medication used in the management and treatment of hemophilia A. It belongs to the bispecific monoclonal antibody class of drugs. Managing patients with HA is complex and requires replacing FVIII for bleeding prophylaxis and treating acute bleeding episodes. Emicizumab was created to circumvent challenges associated with frequent intravenous administration of FVIII and offer a standardized treatment option for Hemophilia A patients with and without inhibitors.

Synonyms

Bispecific, ACE-910, RG6013, hBS910, 1610943-06-0

CAS

1610943-06-0

Isotype

IgG4 - kappa

Host

Human

Target

F9/Factor IX

Reactivity

Human

Expression System

CHO

Applications

ELISA, FC, Functional Assays, IF; Recommended dilution: FC, IF:1:200

Purity

>98% by SDS-PAGE

Concentration

Bottled at the concentration indicated on the vial.

Buffer

0.01M PBS, pH 7.4, contains no stabilizers or preservatives.

Endotoxin

<1.0 EU/mg as determined by LAL method

Conjugation

Non-conjugated

Formulation

Liquid or Lyophilized powder Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Storage

store at -20°C or -80°C. Avoid repeated freeze.

Type

Antibody

Purposes

For research use only

References 1

Bauer KA. Current challenges in the management of hemophilia. Am J Manag Care. 2015 Mar;21(6 Suppl):S112-22.

References 2

Kruse-Jarres R, Kempton CL, Baudo F, Collins PW, Knoebl P, Leissinger CA, Tiede A, Kessler CM. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017 Jul;92(7):695-705.

References 3

Haya S. Prophylactic treatment in hemophilic patients with inhibitors. Blood Coagul Fibrinolysis. 2019 Sep;30(1S Suppl 1):S14-S18. 

References 4

Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan;25(1):33-44. 

References 5

Gelbenegger G, Schoergenhofer C, Knoebl P, Jilma B. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. Thromb Haemost. 2020 Oct;120(10):1357-1370.

Product Citations 1

Product Citations 2

https://www.ncbi.nlm.nih.gov/books/NBK559180/
https://www.oursmab.com/News/The-Coagulation-factor-FIX.html

Target Description

Synonyms

Christmas Factor, F9, FIX, HEMB, P19, Plasma Thromboplastic Component, PTC, THPH8

Biology Area

Innate Immunity;Immunology

Function

Factor IX encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease.

Additional Articles 1

The-Coagulation-factor-FIX

Additional Articles 2

Related Products

Icatolimab (Biosimilar Reference Antibody) (BTLA)

Catalog: 

RA0826

Target：

BTLA/CD272

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Emicizumab (Biosimilar Reference Antibody) (F9/Factor IX)

Catalog: 

RA0826

Target：

F9/Factor IX

Isotype：

IgG4 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Bempikibart (Biosimilar Reference Antibody) (IL7R)

Catalog: 

RA0826

Target：

IL7R/CD127

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Maftivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0826

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Lusvertikimab (Biosimilar Reference Antibody) (IL7R)

Catalog: 

RA0826

Target：

IL7R/CD127

Isotype：

IgG4 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Odesivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0826

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Porgaviximab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0826

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus
Enokizumab (Biosimilar Reference Antibody) (IL9)

Catalog: 

RA0826

Target：

IL9

Isotype：

IgG1 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Bapotulimab (Biosimilar Reference Antibody) (ILDR2)

Catalog: 

RA0826

Target：

ILDR2

Isotype：

IgG2 - kappa

Applications：

ELISA;FC;Functional Assays;IF

Reactivities：

Human
Atoltivimab (Biosimilar Reference Antibody) (Zaire Ebolavirus Glycoprotein)

Catalog: 

RA0826

Target：

Zaire Ebolaviru...

Isotype：

IgG1 - kappa

Applications：

Functional Assays

Reactivities：

Virus

Contact Us

Send your request

Talk to us 

Get a quotation, discuss your requirement, receive advises from our antibody experts without obligation.